CTOs on the Move

Hoosier Oncology Group

www.hoosieroncologygroup.org

 
Hoosier Oncology Group is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ENGAGE Healthcare Business Services

ENGAGE Healthcare Business Services is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Strawn Arnold

Strawn Arnold & Associates, Ltd.. is a premier provider of executive search to the healthcare industry. Our reputation has been built through executing searches for directors of governance boards, all levels of general management, as well as selected functional experts. Many of our Partners are recognized as "best in class" in their market segments. With nearly four decades of service and experience, Strawn Arnold & Associates, Ltd. is unparalleled in the depth of its knowledge and understanding of the healthcare market. Our firm stands for results, integrity and personal service, while providing access to business leaders at the highest level across the industry.

Targeted Medical Pharma

Targeted Medical Pharma Inc. is a leader in the development of therapeutic systems for the nutritional management of chronic diseases. The Company strives to optimize patient care with safe and clinically effective prescription Medical Food products, as well as distributing generic and branded drugs.

St. Joseph Healthcare

St. Joseph Healthcare is a Bangor, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.